Videos

Justin F. Gainor, MD, discusses the latest advancements with immune checkpoint inhibitors for the treatment of patients with non—small cell lung cancer.

David Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br /> &nbsp;

The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.

Margaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in&nbsp;the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.